Gamehost Inc
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2012-01-01
- Employees
- 1.7K
- Market Cap
- -
- Introduction
Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2011 and is headquartered in Palo Alto, CA.
Clinical Trials
9
Trial Phases
0 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Shield Post-Approval Study Protocol
- Conditions
- Colo-rectal Cancer
- First Posted Date
- 2025-03-17
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Guardant Health, Inc.
- Target Recruit Count
- 3375
- Registration Number
- NCT06880055
SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
- Conditions
- Non-small Cell Lung CancerColorectal CancerBreast Cancer
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Guardant Health, Inc.
- Target Recruit Count
- 440
- Registration Number
- NCT05935384
- Locations
- 🇺🇸
Orchard Healthcare Research Inc., Skokie, Illinois, United States
Screening for High Frequency Malignant Disease
- Conditions
- Lung Cancer
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Guardant Health, Inc.
- Target Recruit Count
- 12000
- Registration Number
- NCT05117840
- Locations
- 🇺🇸
University of Alabama Birmingham Lung Health Center, Birmingham, Alabama, United States
🇺🇸Highlands Oncology Group PA, Fayetteville, Arkansas, United States
🇺🇸Pacific Cancer Medical Center, Anaheim, California, United States
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Conditions
- Bladder CarcinomaUreter CarcinomaRenal Pelvis CarcinomaNon-small Cell Lung CancerInvasive Breast CarcinomaCutaneous MelanomaEsophageal CarcinomaGastroesophageal Junction CarcinomaGastric AdenocarcinomaPancreatic Adenocarcinoma
- First Posted Date
- 2021-09-28
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Guardant Health, Inc.
- Target Recruit Count
- 1050
- Registration Number
- NCT05059444
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Ironwood Cancer & Research Centers, Chandler, Arizona, United States
🇺🇸Genesis Cancer Center, Hot Springs, Arkansas, United States
Guardant360® Related Clinical Outcomes in Patients Who Share Medical Records-Breast Cancer
- Conditions
- Advanced Breast Cancer
- First Posted Date
- 2020-06-18
- Last Posted Date
- 2022-06-22
- Lead Sponsor
- Guardant Health, Inc.
- Target Recruit Count
- 109
- Registration Number
- NCT04436393
- Locations
- 🇺🇸
Guardant Health, Redwood City, California, United States
- Prev
- 1
- 2
- Next
News
Guardant Health Launches First Tissue Test with Comprehensive Multiomic Analysis for Cancer Profiling
Guardant Health has launched Guardant360 Tissue, the first molecular profiling test for tumor tissue that incorporates comprehensive multiomics analysis including DNA, RNA, AI-powered PD-L1 and genome-wide methylation data.
Guardant Health and Pfizer Form Strategic Alliance to Advance Cancer Therapies Using Liquid Biopsy Technology
Guardant Health and Pfizer have established a multi-year collaboration to utilize Guardant's Infinity smart liquid biopsy platform in developing and commercializing Pfizer's oncology portfolio.
Guardant Health's Shield Multi-Cancer Detection Test Shows Strong Performance Across 10 Cancer Types
Guardant Health's blood-based Shield Multi-Cancer Detection test demonstrated 98.5% specificity and 60% overall sensitivity across ten tumor types, with particularly strong results for aggressive cancers.
CMS Grants ADLT Status to Guardant Health's Shield Blood Test for Colorectal Cancer Screening
The Centers for Medicare & Medicaid Services (CMS) has approved Advanced Diagnostic Laboratory Test (ADLT) status for Guardant Health's Shield blood test, the first FDA-approved blood test for primary colorectal cancer screening.
Lumos Pharma's Oral LUM-201 Shows Sustained Growth in Pediatric GHD in Phase 2 Trials
Updated Phase 2 data on LUM-201 demonstrate sustained growth over 24 months in children with moderate Pediatric Growth Hormone Deficiency (PGHD).
Personalized Medicine Biomarkers Market Set to Reach $79.26 Billion by 2034, Driven by Precision Oncology and AI
• The global personalized medicine biomarkers market is projected to grow from $21.95 billion in 2024 to $79.26 billion by 2034, representing a CAGR of 13.7% as demand for precision healthcare solutions increases. • Treatment selection dominates the market with 50.2% share, while oncology leads indication segments at 36.0%, reflecting the critical role of biomarkers in matching patients to targeted cancer therapies. • North America currently holds 52.0% of market share, with the U.S. market alone expected to grow at 15.5% CAGR to reach $40.90 billion by 2034, driven by technological advancements and regulatory support.
FDA Approves Shield Blood Test for Colorectal Cancer Screening
The FDA has approved Shield, the first blood test for primary colorectal cancer screening, offering a less invasive option for average-risk adults.
FDA Approves Guardant Health's Shield Blood Test for Colorectal Cancer Screening
The FDA has approved Guardant Health's Shield blood test for colorectal cancer screening, marking a significant step towards broader access to CRC detection.
Global Lung Ambition Alliance Takes Aim at Three Major Challenges in Lung Cancer Care
The Lung Ambition Alliance, a partnership of major healthcare organizations, aims to double five-year lung cancer survival rates by 2025 through improved screening, innovative medicines, and enhanced quality of care.